Bushnell D - Search Results

1

High-specific-activity ¹³¹iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma.

Dillon JS, Bushnell D, Laux DE. Dillon JS, et al. Among authors: bushnell d. Future Oncol. 2021 Apr;17(10):1131-1141. doi: 10.2217/fon-2020-0625. Epub 2021 Jan 28. Future Oncol. 2021. PMID: 33506713 Free PMC article.

2

⁹⁰Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.

Menda Y, Madsen MT, O'Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. Menda Y, et al. Among authors: bushnell dl. J Nucl Med. 2018 Nov;59(11):1692-1698. doi: 10.2967/jnumed.117.202903. Epub 2018 Mar 9. J Nucl Med. 2018. PMID: 29523629 Free PMC article. Clinical Trial.

3

Localization of Unknown Primary Site with ⁶⁸Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.

Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS. Menda Y, et al. Among authors: bushnell dl. J Nucl Med. 2017 Jul;58(7):1054-1057. doi: 10.2967/jnumed.116.180984. Epub 2017 Feb 2. J Nucl Med. 2017. PMID: 28153957 Free PMC article. Clinical Trial.

4

Addition of ¹³¹I-MIBG to PRRT (⁹⁰Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors.

Bushnell DL, Bodeker KL, O'Dorisio TM, Madsen MT, Menda Y, Graves S, Zamba GKD, O'Dorisio MS. Bushnell DL, et al. J Nucl Med. 2021 Sep 1;62(9):1274-1277. doi: 10.2967/jnumed.120.254987. Epub 2021 Jan 30. J Nucl Med. 2021. PMID: 33517327 Free PMC article. Clinical Trial.

5

Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.

Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, Besse IM. Madsen MT, et al. J Nucl Med. 2006 Apr;47(4):660-7. J Nucl Med. 2006. PMID: 16595501 Free article.

6

Overview and Current Status of Peptide Receptor Radionuclide Therapy.

Bushnell DL, Bodeker KL. Bushnell DL, et al. Surg Oncol Clin N Am. 2020 Apr;29(2):317-326. doi: 10.1016/j.soc.2019.11.005. Surg Oncol Clin N Am. 2020. PMID: 32151363 Review.

7

Potential for Increasing Uptake of Radiolabeled ⁶⁸Ga-DOTATOC and ¹²³I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.

Pollard JH, Menda Y, Zamba KD, Madsen M, O'Dorisio MS, O'Dorisio T, Bushnell D. Pollard JH, et al. Among authors: bushnell d. Cancer Biother Radiopharm. 2021 Oct;36(8):632-641. doi: 10.1089/cbr.2020.4633. Epub 2021 Jul 12. Cancer Biother Radiopharm. 2021. PMID: 34252288 Free PMC article.

8

Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules.

Bushnell D. Bushnell D. J Natl Compr Canc Netw. 2009 Jul;7(7):760-4. doi: 10.6004/jnccn.2009.0052. J Natl Compr Canc Netw. 2009. PMID: 19635228

9

A comparison between diagnostic I-123 and posttherapy I-131 scans in the detection of remnant and locoregional thyroid disease.

Thomas DL, Menda Y, Bushnell D. Thomas DL, et al. Among authors: bushnell d. Clin Nucl Med. 2009 Nov;34(11):745-8. doi: 10.1097/RLU.0b013e3181b7dbb1. Clin Nucl Med. 2009. PMID: 19851166

10

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, LaFrance N, Pauwels SA. Bushnell DL Jr, et al. J Clin Oncol. 2010 Apr 1;28(10):1652-9. doi: 10.1200/JCO.2009.22.8585. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194865 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

291 results

Search Page

Filters